Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$11.12
At close: Jun 20 EDT
$11.04
-0.08-0.72%
Pre-Market: 5:54 AM EDT
Comments
Loading...
Verve Therapeutics Analyst Ratings and Price Targets | NASDAQ:VERV | Benzinga
Verve Therapeutics Inc has a consensus price target of $23.45 based on the ratings of 13 analysts. The high is $62 issued by BMO Capital on July 18, 2022. The low is $11 issued by Jefferies on June 18, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co., LifeSci Capital, and Jefferies on June 18, 2025, respectively. With an average price target of $12.17 between HC Wainwright & Co., LifeSci Capital, and Jefferies, there's an implied 10.21% upside for Verve Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
LifeSci Capital
Jefferies
Canaccord Genuity
Guggenheim
1calculated from analyst ratings
Analyst Ratings for Verve Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/18/2025 | Buy Now | 22.28% | HC Wainwright & Co. | Mitchell Kapoor46% | $13.5 → $13.5 | Downgrade | Buy → Neutral | Get Alert |
| 06/18/2025 | Buy Now | 8.7% | LifeSci Capital | Cory Jubinville42% | → $12 | Downgrade | Outperform → Market Perform | Get Alert |
| 06/18/2025 | Buy Now | -0.36% | Jefferies | Roger Song36% | $28 → $11 | Downgrade | Buy → Hold | Get Alert |
| 06/17/2025 | Buy Now | — | William Blair | Myles Minter38% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 06/17/2025 | Buy Now | 17.75% | Canaccord Genuity | Whitney Ijem57% | $39 → $13 | Downgrade | Buy → Hold | Get Alert |
| 04/15/2025 | Buy Now | — | Cantor Fitzgerald | Rick Bienkowski28% | — | Upgrade | Neutral → Overweight | Get Alert |
| 04/15/2025 | Buy Now | 117.39% | Guggenheim | Etzer Darout48% | $18 → $24 | Maintains | Buy | Get Alert |
| 04/15/2025 | Buy Now | 253.26% | Canaccord Genuity | Whitney Ijem57% | $32 → $39 | Maintains | Buy | Get Alert |
| 04/14/2025 | Buy Now | 126.45% | HC Wainwright & Co. | Mitchell Kapoor46% | $15 → $25 | Maintains | Buy | Get Alert |
| 03/25/2025 | Buy Now | — | Guggenheim | Seamus Fernandez61% | — | Reiterates | Buy → Buy | Get Alert |
| 03/25/2025 | Buy Now | 35.87% | HC Wainwright & Co. | Mitchell Kapoor46% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 03/04/2025 | Buy Now | 35.87% | RBC Capital | Luca Issi44% | $17 → $15 | Maintains | Outperform | Get Alert |
| 02/28/2025 | Buy Now | 35.87% | HC Wainwright & Co. | Mitchell Kapoor46% | $14 → $15 | Maintains | Buy | Get Alert |
| 11/06/2024 | Buy Now | 189.86% | Canaccord Genuity | Whitney Ijem57% | $29 → $32 | Maintains | Buy | Get Alert |
| 11/06/2024 | Buy Now | 53.99% | RBC Capital | Luca Issi44% | $20 → $17 | Maintains | Outperform | Get Alert |
| 11/06/2024 | Buy Now | 26.81% | HC Wainwright & Co. | Mitchell Kapoor46% | $15 → $14 | Maintains | Buy | Get Alert |
| 08/12/2024 | Buy Now | 162.68% | Canaccord Genuity | Whitney Ijem57% | $30 → $29 | Maintains | Buy | Get Alert |
| 08/12/2024 | Buy Now | 35.87% | HC Wainwright & Co. | Mitchell Kapoor46% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2024 | Buy Now | 81.16% | RBC Capital | Luca Issi44% | $25 → $20 | Maintains | Outperform | Get Alert |
| 05/09/2024 | Buy Now | 35.87% | HC Wainwright & Co. | Mitchell Kapoor46% | → $15 | Reiterates | Buy → Buy | Get Alert |
| 04/03/2024 | Buy Now | 262.32% | Stifel | Dae Gon Ha47% | $56 → $40 | Maintains | Buy | Get Alert |
| 02/28/2024 | Buy Now | 217.03% | RBC Capital | Luca Issi44% | $35 → $35 | Reiterates | Outperform → Outperform | Get Alert |
| 09/13/2023 | Buy Now | 99.28% | Cantor Fitzgerald | Rick Bienkowski28% | → $22 | Reiterates | Neutral → Neutral | Get Alert |
| 08/29/2023 | Buy Now | 99.28% | Cantor Fitzgerald | Rick Bienkowski28% | → $22 | Reiterates | Neutral → Neutral | Get Alert |
| 08/15/2023 | Buy Now | 398.19% | Guggenheim | Seamus Fernandez61% | $56 → $55 | Maintains | Buy | Get Alert |
| 08/11/2023 | Buy Now | 180.8% | Credit Suisse | Richard Law46% | → $31 | Reiterates | Neutral → Neutral | Get Alert |
| 06/16/2023 | Buy Now | 162.68% | Canaccord Genuity | Whitney Ijem57% | → $29 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2023 | Buy Now | 217.03% | RBC Capital | Luca Issi44% | → $35 | Reiterates | Outperform → Outperform | Get Alert |
| 04/13/2023 | Buy Now | 162.68% | Canaccord Genuity | Whitney Ijem57% | → $29 | Initiates | → Buy | Get Alert |
| 02/01/2023 | Buy Now | 90.22% | Cantor Fitzgerald | Rick Bienkowski28% | → $21 | Initiates | → Neutral | Get Alert |
| 12/15/2022 | Buy Now | 17.75% | Goldman Sachs | Andrea Tan40% | → $13 | Initiates | → Sell | Get Alert |
| 11/08/2022 | Buy Now | 217.03% | RBC Capital | Luca Issi44% | $42 → $35 | Maintains | Outperform | Get Alert |
| 10/06/2022 | Buy Now | 334.78% | Credit Suisse | Richard Law46% | → $48 | Initiates | → Neutral | Get Alert |
| 08/25/2022 | Buy Now | 407.25% | Stifel | Dae Gon Ha47% | $32 → $56 | Upgrade | Hold → Buy | Get Alert |
| 07/18/2022 | Buy Now | 461.59% | BMO Capital | Kostas Biliouris34% | $48 → $62 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Verve Therapeutics (VERV) stock?
The latest price target for Verve Therapeutics (NASDAQ:VERV) was reported by HC Wainwright & Co. on June 18, 2025. The analyst firm set a price target for $13.50 expecting VERV to rise to within 12 months (a possible 22.28% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Verve Therapeutics (VERV)?
The latest analyst rating for Verve Therapeutics (NASDAQ:VERV) was provided by HC Wainwright & Co., and Verve Therapeutics downgraded their neutral rating.
When was the last upgrade for Verve Therapeutics (VERV)?
The last upgrade for Verve Therapeutics Inc happened on April 15, 2025 when Cantor Fitzgerald raised their price target to N/A. Cantor Fitzgerald previously had a neutral for Verve Therapeutics Inc.
When was the last downgrade for Verve Therapeutics (VERV)?
The last downgrade for Verve Therapeutics Inc happened on June 18, 2025 when HC Wainwright & Co. changed their price target from $13.5 to $13.5 for Verve Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Verve Therapeutics (VERV)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Verve Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Verve Therapeutics was filed on June 18, 2025 so you should expect the next rating to be made available sometime around June 18, 2026.
Is the Analyst Rating Verve Therapeutics (VERV) correct?
While ratings are subjective and will change, the latest Verve Therapeutics (VERV) rating was a downgraded with a price target of $13.50 to $13.50. The current price Verve Therapeutics (VERV) is trading at is $11.04, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
